Introduction
Recombinant granulocyte (rhG)-CSF is a haematopoietic growth factor that stimulates the proliferation and differentiation of neutrophil precursor cells. 1 RhG-CSF-mobilized peripheral blood cells collected by apheresis as a source of haematopoietic progenitor cells (HPC-A) are increasingly employed for allogeneic transplantation in patients with haematological and non-haematological malignancies as an alternative to BMT. 2, 3 Avoiding general anaesthesia, surgery (marrow harvesting) and autologous or allogeneic blood transfusions in donors have the potential of making the donation safer, less traumatic and more effective in collecting HPC-A. 4 Although the short-term toxicities of rhG-CSF in donors are well known, [5] [6] [7] [8] [9] data on the long-term impact of rhG-CSF in normal donors are scarce, and only a few series involving small numbers of donors have addressed these issues. [10] [11] [12] [13] More widespread use of allogeneic HPC-A may be limited because of the potential risks of the long-term effects of rhG-CSF, [14] [15] [16] [17] [18] [19] [20] [21] [22] although there are no data in this regard in healthy donors (HDs). 10, 11, 13, 16, 17, [23] [24] [25] The aim of the present prospective single-institution study was to assess the short-and long-term side effects in a population of HDs treated with rhG-CSF and subjected to HPC-A collection.
Patients and methods
A total of 184 consecutive related HDs received lenograstim (LENO) as the rhG-CSF mobilization agent. LENO was given s.c. at a total median dose of 10 mg/kg (range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] in two refracted doses every 12 h for 4-7 days, according to the different schedules reported by the literature. [26] [27] [28] All injections were given at the same time in the morning and in the evening after blood sampling. The day of pre-treatment evaluation and the first day of LENO administration were conventionally considered as day 0 and day 1, respectively. Prophylaxis with paracetamol was administered to prevent the potential side effects of LENO. In all cases, the first LENO administration was carried out in the hospital, and was then continued on an outpatient basis at the donor's home, either as a self-administration or as an injection given by the subject's family physician.
All donors were enrolled after written informed consent, according to the ethical committee of our hospital and the national and international guidelines for allogeneic BM donations, 29, 30 and after a detailed description of the potential side effects and risks of rhG-CSF mobilization and apheresis compared with BM donations. HDs were informed about the possible long-term effects of rhG-CSF, such as the possibility of developing tumours or leukaemia as shown by in vitro and in vivo experiments. 31 After the administration of rhG-CSF, CD34 þ cells were monitored on day 4 and daily thereafter, until the completion of apheresis. HPC-A collection was started as soon as the detectable circulating CD34 þ cells exceeded the cutoff value of 20/ml (on day [4] [5] [6] . If the target CD34 þ cell dose was not reached in a single procedure, rhG-CSF was administered for another day until the target value was reached. Apheresis was carried out with continuous-flow apheresis equipment (AS 104/AS 204 and COM.TEC cell seperators, Fresenius Hemo-Care GmbH, Bad Homburg, Germany) using citrate-dextrose as the anticoagulant. Blood was processed in all HDs through the antecubital vein, and no donor needed a central venous catheter. HDs, who after one or two apheresis procedures had reached the minimal number of CD34 þ cells, were considered acceptable for allotransplantation (X4 Â 10 6 CD34 þ cells per kg body wt) and allowed to continue HPC-A collection at the discretion of the attending physician for apheresis. LENO was continued until the completion of HPC-A collection.
The aim of this prospective study was to assess the shortand long-term side effects in a population of HDs who were treated with LENO and subjected to HPC-A collection in an apheresis unit. For this purpose, short-and long-term adverse events were defined as follows: (a) short-term (any death within 30 days from donation; any mild adverse event within 30 days; any severe adverse event within 30 days requiring hospitalization); (b) long-term (any haematological or non-haematological malignancy at any time postdonation; any acute/chronic disease post-donation, starting from 1 month after donation).
Donors were seen at our institution 2-3 weeks before the start of mobilization. The workup included a detailed history, clinical examination, abdominal ultrasound and an electrocardiogram. Laboratory evaluation included blood counts and differentials, clinical chemistry, infectious disease markers and b-human chorionic gonadotropin in female donors to exclude pregnancy. In donors with venous access not suitable for performing apheresis, the stem cells were collected by BM harvest, but were not entered in this study.
All donors received written information from their general practitioner explaining the procedure and the use of growth factors in this setting, and they were informed about the need for long-term and worldwide collection of follow-up data. Subjects were also informed that, in the case of headaches or bone pain, they could take paracetamol at the prescribed dosage. All donors were asked to rate rhG-CSF-related adverse events as mild (grade 1), moderate (grade 2) or severe (grade 3). RhG-CSF-related adverse events that prompted the discontinuation of the drug were rated as grade 4. For statistical analysis, a Pearson's w 2 test was used for sex, age and dose of rhG-CSF, whereas a two-tailed P-value o0.05 was considered statistically significant.
Healthy donors were monitored daily by clinical examination and blood count/chemistry analyses during rhG-CSF administration, and every 3-4 days during follow-up until the normalization of blood counts. Subsequently, the subjects were monitored prospectively by clinical examination and haematological parameters every 6 months during the first year of follow-up, and once a year after 5 years.
If the donors were unable to come to the hospital, they were solicited yearly by mail and/or by telephone to send the most recent haematological analyses. All data were collected in a dedicated Excel database.
Results
All the 184 HDs completed the mobilization protocol without interruption or reduction in the scheduled growthfactor dosage. The median age was 44 years (range 15-66), and only one donor was o18 years old (15 years). The main characteristics of the HDs are summarized in Table 1 . The median duration of LENO administration was 5 days (4-8 days). Bone pain was the most common short-term adverse event that was reported by 71.2% of the donors, particularly in the back and pelvis. In all, 27.7% of the donors reported headache, 22.3% insomnia, 19% fatigue, 12% nausea and 5.4% fever ( Table 2 ). The incidence of headache and fatigue increased when LENO was given at a dose of X9 mg/kg/day (P ¼ 0.02 and P ¼ 0.04 respectively); bone pain also increased in the same subset of donors (P ¼ 0.006) ( Table 3) . Nausea was higher in female donors (P ¼ 0.002). The incidence of other symptoms with sex, age and dose of rhG-CSF failed to show any statistical difference (Tables 3 and 4 ). Spleen size increased in 4.3% of the donors (42 cm exceeding the costal marginal at physical examination). Six donors were hospitalized for side effects, generally related to splenomegaly, and the hospitalization was decided for closer monitoring of the donors. All side effects were resolved within 2-4 days after discontinuation of LENO.
The median dose of CD34 þ cells collected was 9 Â 10 6 /kg (range 0-25). The target amount of blood to be processed was B3 times the donor's blood volume for at least the first collection. Problems with venous access were seen in 15 HDs, resulting in blood-flow alarms and blockades in the return line, but no procedure had to be discontinued for this reason. Mild bleeding at the site of venipuncture was observed in two HDs. Five donors failed HPC-A mobilization. The main apheretic data are summarized in Table 5 .
Leukocytes rapidly increased to a median count of 48 Â 10 9 /l (range 19-85) after 4-6 days of rhG-CSF administration. During rhG-CSF administration, there was no significant change in either Hb levels or plt counts.
Immediately after apheresis, there was a decrease in plt counts to a median of 91 Â 10 bleeding complications. Hb levels decreased slightly. The median recovery of WBC and plt counts was on day 10 (range 5-47) and day 8 (range 0-28), respectively. Hb levels and plt counts showed no significant differences compared with baseline values after 6 months. Four donors showed slight persistent leukocytopenia until the fourth month of follow-up.
Long-term follow-up included the monitoring of adverse events in donors after 30 days from HPC-A mobilization and any neoplastic or non-neoplastic pathology at any time post-donation. About 50% of HDs were examined yearly in our hospital; 20% of HDs answered by e-mail and the rest were contacted by telephone. The median follow-up was 62 months (range 2-155); for 70 subjects it was 474 months and for 33 subjects it was 496 months. A total of 19 donors showed an aspartate aminotransferase and alanine aminotransferase that were 2.5 times the upper normal limits until the second month of follow-up, whereas other biochemical parameters did not show significant variations. Transit ischaemic attack occurred in one donor, (39 months post-donation). One auto-immune event was reported at 28 months post-rhG-CSF (ankylosing spondylitis); one donor with a history of chronic obstructive pulmonary disease developed secondary polyglobulia (50 months post-rhG-CSF). During follow-up, one male donor with a history of tobacco smoking developed lung cancer at 19 months post-donation. At the time of writing, no haematological malignancies have been reported.
Discussion
Documenting the safety of rhG-CSF as a mobilizing agent for HPC-A donation has long been a matter of importance for physicians, particularly when made by volunteer, unrelated adult donors. The short-term adverse events experienced by HPC-A donors after mobilization with rhG-CSF are well known. The most frequently described events are mild to moderate in nature and include bone pain, headache, nausea, insomnia, fever, fatigue and reversible changes in laboratory parameters such as increased levels of lactate dehydrogenase and alkaline phosphatase, in addition to thrombocytopenia. [7] [8] [9] Despite this, isolated cases of severe clinical involvement such as substantial increases in spleen size and, in some cases, a rupture of the organ have been reported. [32] [33] [34] [35] [36] [37] [38] [39] [40] In this study, the short-term clinical adverse side effects were similar to those described in earlier studies. Bone pain was most frequent, although some reports have shown a relationship between the dose of rhG-CSF and the frequency of bone pain. 41, 42 In our HDs, the incidence of bone pain increased, although not significantly, when LENO was given at a dose of X9 mg/kg/day. The LENO dose was associated with a higher incidence of headache, even though to date there have been no reported associations between rhG-CSF dose and headache. Although it could be that the headache had a cause other than hyperleukocytosis, in our study population the peak of leukocytes in donors with headache was similar to that in other donors (data not shown). We also observed that women were more likely to experience nausea, in agreement with an earlier report. 41 Taken together, the present data on the short-term safety of LENO in healthy donors indicate that it is generally well tolerated. All donors were able to complete the mobilization protocol without interruption or reduction of the scheduled growth-factor dosage.
Post-donation cytopenia, which is a well-known adverse effect in HPC-A donors, is related to the apheresis Healthy donors safety and rhG-CSF M Martino et al procedure, which removes a large number of blood cells, although an additional rhG-CSF-related effect cannot be ruled out. 13, 24, 25 In this study, only four donors experienced slight leukopaenia that resolved within 4 months after the donation. This is in contrast to two recent studies that observed a prolonged decrease in WBC count in some donors lasting up to 2 years after rhG-CSF administration, 25 moderate neutrophil reduction and persistent, slight lymphocytopaenia until the third year, with recovery in the fourth year. 13 Another area of debate is the potential thrombotic risk associated with rhG-CSF. In our series, transit ischaemic attack occurred in one donor at 39 months after donation. Some authors observed changes in the activation status of neutrophils in HDs receiving rhG-CSF, which may be associated with changes in endothelial cells and clotting activation markers, in addition to changes in the procoagulant response. 43 The abnormalities in plasma markers are transient and related to drug administration. Reports from the German Donor Registry 34 provide information on vascular disorders in over 3000 HPC-A donors mobilized with rhG-CSF. In this cohort, three strokes and one myocardial infarction occurred between 3 months and 2.5 years after donation. One BM donor developed transverse myelitis (Brown-Sequard syndrome). These data, together with our results, suggest that the transient but significant alteration of haemostatic markers reported in the literature do not indicate a genuine thrombotic risk for healthy individuals.
To date, there is little information about the long-term consequences in healthy donors mobilized with rhG-CSF, or whether this drug can induce or contribute to leukaemogenesis in normal subjects. Laboratory studies indicate that rhG-CSF administration may have leukaemogenic potential in malignant cells, but these findings are non-specific and can be also found in non-malignant cells. The Research on Adverse Drug Events and Reports project 17 identified two donors treated with rhG-CSF who subsequently developed AML, and there are also reports of other isolated cases of leukaemia occurring in volunteer donors at 4-5 years after exposure to rhG-CSF. 19, 44 After a median follow-up of 5 years, we detected no haematological malignancies in our group of donors. One possibility is that the cases described in the literature reflect an increased genetic risk in relatives of patients with leukaemia. It is interesting to highlight that in our series the follow-up for 70 subjects is 474 months and that for 33 subjects it is 496 months. The only neoplastic event occurring after rhG-CSF administration was lung cancer in a heavy smoker, which is one of the most common cancers in western countries.
No other unusual diseases were observed among donors in this study, which is one of the longest follow-ups of such donors to date. Single-site studies of adult HPC-A donors have not shown long-term effects associated with rhG-CSF therapy, with the longest follow-up now at 5 years. [10] [11] [12] [13] A recent study by the Spanish National Donor Registry followed donors for 2 years or more and reported five patients with solid tumours after rhG-CSF administration (lung cancer in two patients and thyroid carcinoma, choroid melanoma and colon carcinoma in one patient each), but no haematological diseases. 25 In conclusion, our surveillance protocol of adverse events occurring after the administration of LENO to healthy individuals shows that the short-term safety appears to be verified and described as mild to moderate, and that the most frequent toxicity is bone pain, with no cardiovascular events, acute lung injury or death.
Although the absence of leukaemia and lymphoma in our cohort of volunteers, as well as the low occurrence of haematological diseases in other studies, should provide reassurance to individuals who receive rhG-CSF for HPC-A mobilization, long-term safety requires more complete Healthy donors safety and rhG-CSF M Martino et al data sets, especially a longer follow-up and a larger number of patients. The apheresis unit should further encourage their participation in carefully designed programmes for follow-up monitoring. As data from these and other studies become available, more complete assessment of overall donor safety will become known. We will continue to maintain a 5-year surveillance period and also extend the follow-up observation to 10 years in older donors and in those whose rhG-CSF treatment is carried out in our institution.
